Skip to main content

Efficacy and safety of tacrolimus ointment 0.03% treatment in a 1-month-old "red baby": A case report

Buy Article:

$39.50 plus tax (Refund Policy)


Several trials have indicated that topical tacrolimus is safe and effective for several immunologic-based skin disorders. We report a child <2 months old, who was admitted to our pediatric department because of generalized erythroderma. We started tacrolimus ointment 0.03% therapy by applying the ointment to the skin once daily, on a limited surface of 10 cm2, changing the skin areas only after the disappearance of inflammation. After only one application we observed a marked improvement of the treated area and after another application the localized erythroderma disappeared. We changed the site of application and continued this treatment regime for 4 weeks. After 2 weeks we reduced treatment application once every other day and after an additional 2 weeks we discontinued therapy because of complete resolution of erythroderma. No adverse clinical effect was recorded and tolerance to the treatment was good. We conclude that 0.03% tacrolimus ointment is efficacious and safe even in an infant <2 months of age.

Document Type: Research Article


Publication date: 2006-11-01

More about this publication?
  • Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.

    The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.

    Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.

    Articles marked "F" offer free full text for personal noncommercial use only.

    The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Information for Advertisers
  • Reprint Requests
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more